Found: 132
Select item for more details and to access through your institution.
Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model.
- Published in:
- Journal of Gene Medicine, 2006, v. 8, n. 3, p. 253, doi. 10.1002/jgm.840
- By:
- Publication type:
- Article
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. E15, doi. 10.1002/ajh.26602
- By:
- Publication type:
- Article
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 1, p. 29, doi. 10.1007/s40261-021-01100-y
- By:
- Publication type:
- Article
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-35358-3
- By:
- Publication type:
- Article
Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real‐world practice.
- Published in:
- Cytometry. Part B, 2023, v. 104, n. 4, p. 304, doi. 10.1002/cyto.b.22100
- By:
- Publication type:
- Article
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 5, p. 504, doi. 10.1111/ejh.13835
- By:
- Publication type:
- Article
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
- Published in:
- European Journal of Haematology, 2019, v. 103, n. 2, p. 107, doi. 10.1111/ejh.13264
- By:
- Publication type:
- Article
The start of a new wave: Developments in proteasome inhibition in multiple myeloma.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 2, p. 220, doi. 10.1111/ejh.13071
- By:
- Publication type:
- Article
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.703233
- By:
- Publication type:
- Article
Physical Activity During and After Haematological Cancer Treatment: A Cross-Sectional Survey of Haematology Healthcare Professionals in the United Kingdom.
- Published in:
- Journal of Multidisciplinary Healthcare, 2021, v. 14, p. 1659, doi. 10.2147/JMDH.S295888
- By:
- Publication type:
- Article
"What I wanted to do was build myself back up and prepare": qualitative findings from the PERCEPT trial of prehabilitation during autologous stem cell transplantation in myeloma.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10799-1
- By:
- Publication type:
- Article
P-217: Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S159, doi. 10.1016/S2152-2650(21)02344-2
- By:
- Publication type:
- Article
P-039: Adaptation of a myeloma minimal residual disease multi-parametric flow assay for real world practice.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S59, doi. 10.1016/S2152-2650(21)02173-X
- By:
- Publication type:
- Article
MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S420, doi. 10.1016/S2152-2650(21)01942-X
- By:
- Publication type:
- Article
Poster: MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01570-6
- By:
- Publication type:
- Article
Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis – a first report.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e309, doi. 10.1016/j.clml.2019.09.508
- By:
- Publication type:
- Article
Real World Use of Ixazomib With Lenalidomide and Dexamethasone for Patients With Relapsed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e264, doi. 10.1016/j.clml.2019.09.436
- By:
- Publication type:
- Article
Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e254, doi. 10.1016/j.clml.2019.09.420
- By:
- Publication type:
- Article
Comparison of PET Reconstruction Algorithms on Assessment and Quantification of FDG-PETCT Findings in Patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e171, doi. 10.1016/j.clml.2019.09.286
- By:
- Publication type:
- Article
Durability of Response and Characterisation of Corneal events with Extended follow-up after Belantamab Mafodotin monotherapy for patients with relapsed/refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e150, doi. 10.1016/j.clml.2019.09.250
- By:
- Publication type:
- Article
Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e33, doi. 10.1016/j.clml.2019.09.049
- By:
- Publication type:
- Article
Real World Data of the Impact of first cycle Daratumumab on Multiple Myeloma and Amyloidosis Services.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e157, doi. 10.1016/j.clml.2017.03.284
- By:
- Publication type:
- Article
Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to.
- Published in:
- European Journal of Cancer Care, 2011, v. 20, n. 5, p. 697, doi. 10.1111/j.1365-2354.2011.01248.x
- By:
- Publication type:
- Article
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment.
- Published in:
- International Seminars in Surgical Oncology, 2004, v. 1, p. 7, doi. 10.1186/1477-7800-1-7
- By:
- Publication type:
- Article
663. Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Reverse Osteoclast Activation in a Xenogeneic Murine Model of Multiple Myeloma.
- Published in:
- Molecular Therapy, 2006, v. 13, p. S256, doi. 10.1016/j.ymthe.2006.08.740
- By:
- Publication type:
- Article
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00717-2
- By:
- Publication type:
- Article
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 11, p. 1, doi. 10.1038/s41408-020-00370-7
- By:
- Publication type:
- Article
Engraftment defect of cytokine-cultured adult human mobilized CD34<sup>+</sup> cells is related to reduced adhesion to bone marrow niche elements.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 6, p. 778, doi. 10.1111/j.1365-2141.2012.09219.x
- By:
- Publication type:
- Article
Improved response with post- ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 4, p. 499, doi. 10.1111/j.1365-2141.2012.09188.x
- By:
- Publication type:
- Article
Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma.
- Published in:
- British Journal of Haematology, 2012, v. 157, n. 4, p. 494, doi. 10.1111/j.1365-2141.2011.09023.x
- By:
- Publication type:
- Article
Guidelines for the diagnosis and management of multiple myeloma 2011.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 1, p. 32, doi. 10.1111/j.1365-2141.2011.08573.x
- By:
- Publication type:
- Article
CD20-positive multiple myeloma – differential expression of cyclins D1 and D2 suggests a heterogeneous disease.
- Published in:
- 2010
- By:
- Publication type:
- Letter
Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
- Published in:
- British Journal of Haematology, 2007, v. 139, n. 2, p. 243, doi. 10.1111/j.1365-2141.2007.06789.x
- By:
- Publication type:
- Article
Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation.
- Published in:
- British Journal of Haematology, 2007, v. 138, n. 3, p. 281, doi. 10.1111/j.1365-2141.2007.06622.x
- By:
- Publication type:
- Article
Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2005, v. 129, n. 6, p. 763, doi. 10.1111/j.1365-2141.2005.05521.x
- By:
- Publication type:
- Article
Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.
- Published in:
- British Journal of Haematology, 2004, v. 125, n. 6, p. 756, doi. 10.1111/j.1365-2141.2004.04981.x
- By:
- Publication type:
- Article
T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions
- Published in:
- British Journal of Haematology, 2003, v. 123, n. 2, p. 309, doi. 10.1046/j.1365-2141.2003.04612.x
- By:
- Publication type:
- Article
Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation.
- Published in:
- British Journal of Haematology, 2003, v. 120, n. 1, p. 154, doi. 10.1046/j.1365-2141.2003.04036.x
- By:
- Publication type:
- Article
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
- Published in:
- British Journal of Haematology, 2002, v. 119, n. 4, p. 1125, doi. 10.1046/j.1365-2141.2002.03992.x
- By:
- Publication type:
- Article
Influence of cell cycling and cell division on transendothelial migration of CD34<sup>+</sup> cells.
- Published in:
- British Journal of Haematology, 2002, v. 119, n. 2, p. 500, doi. 10.1046/j.1365-2141.2002.03837.x
- By:
- Publication type:
- Article
Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS<sup>®</sup> (v2·1) and Isolex<sup>®</sup> 300i (v2·5) clinical scale devices.
- Published in:
- British Journal of Haematology, 2002, v. 118, n. 1, p. 117, doi. 10.1046/j.1365-2141.2002.03561.x
- By:
- Publication type:
- Article
Fetal haemopoietic cells display enhanced migration across endothelium.
- Published in:
- British Journal of Haematology, 2002, v. 116, n. 2, p. 392, doi. 10.1046/j.1365-2141.2002.03273.x
- By:
- Publication type:
- Article
Challenges in designing and running smouldering myeloma interventional clinical trials.
- Published in:
- 2024
- By:
- Publication type:
- Abstract